Photo from wikipedia
The use of PARP inhibitors as first-line maintenance therapy for advanced ovarian cancer improves progression-free survival, according to three phase III studies. The data also suggest that patients other than… Click to show full abstract
The use of PARP inhibitors as first-line maintenance therapy for advanced ovarian cancer improves progression-free survival, according to three phase III studies. The data also suggest that patients other than those with BRCA1/2 mutations may benefit from this class of drugs.
Keywords:
ovarian cancer;
cancer;
line parp;
first line;
success first
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!